Left ventricular assist devices in end-stage heart failure with “fixed” pulmonary hypertension-a test of reversibility?
Fang JC, DeMArco T, Givertz MM et al World Health Organization Pulmonary Hypertension Group 2: Pulmonary hypertension due to left heart disease in the adult- a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation J Heart Lung Transplant 2012; 31:913-33
Costard-Jäckle A, Fowler MB. Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. J Am Coll Cardiol 1992; 19:48-54.
Goland S, Czer LS, Kass RM, et al. Pre-existing pulmonary hypertension in patients with end-stage heart failure: impact on clinical outcome and hemodynamic follow-up after orthotopic heart transplantation. J Heart Lung Transplant 2007; 26:312-318.
Ozturk P, Engin AY, Nalbantgil S, et al. Comparison of continuous-flow and pulsatile-flow blood pumps on reducing pulmonary artery pressure in patients with fixed pulmonary hypertension. Artif Organs. 2013;37:763-67
Mikus E, Stapanenko A, Krabatsch T, et al. Reversibility of fixed pulmonary hypertension in left ventricular assist device support recipients. Eur J Cardiothorac Surg 2011;40:971-977.
Slaughter MS, Pagani FD, Rogers JG et al Clinical management of continuous-flow left ventricular assist devices in advanced heart failure J Heart Lung Transplantation 2010;29:S1-S39.
Etz CD, Welp HA, Tjan TD, et al. Medically refractory pulmonary hypertension treatment with nonpulsatile left ventricular assist devices. Ann Thorac Surg 2007; 83:1697-1705.
Zimpfer D, Zrunek P, Sandner S, et al. Post-transplant survival after lowering fixed pulmonary hypertension using left ventricular assist devices. Eur J Cardiothorac Surg 2007;31:698-702
Salzberg SP, Lachat ML, von Harbou K, et al. Normalization of high pulmonary vascular resistance with LVAD support in heart transplantation candidates. Eur J Cardiothorac Surg 2005; 27:222-225.
Nair PK, Kormos RL, Teuteberg JJ, et al. Pulsatile left ventricular assist device support as a bridge to decision in patients with end-stage heart failure complicated bypulmonary hypertension. J Heart Lung Transplant 2010; 29:201–208. 11. Kutty RS, Parameshwar J, Lewis C, et al. Use of centrifugal left ventricular assist device as a bridge to candidacy in severe heart failure with secondary pulmonary hypertension Eur J Cardiothorac Surg 2013; 43:1237-42.
Klodell CT Jr, Morey TE, Lobato EB, et al. Effect of sildenafil on pulmonary artery pressure, systemic pressure, and nitric oxide utilization in patients with left ventricular assist devices. Ann Thorac Surg. 2007; 83:68-71.
LaRue SJ, Garcia-Cortes R, Nassif ME, et al Treatment of secondary pulmonary hypertension with bosentan after left ventricular assist device implantation. Cardiovasc Ther. 2015; 33:50-5.
Adamson RM, Dembitsky WP, Jaski BE, et al. Left ventricular assist device support of medically unresponsive pulmonary hypertension and aortic insufficiency. Am Soc Artif Intern Organs J 1997; 43:365-369.
Martin J, Siegenthaler MP, Friesewinkel O, et al. Implantable left ventricular assist device for treatment of pulmonary hypertension in candidates for orthotopic heart transplantation-a preliminary study. Eur J Cardiothorac Surg 2004;25:971-7
Zimpfer D, Zrunek P, Sandner S, et al. Post-transplant survival after lowering fixed pulmonary hypertension using left ventricular assist devices. Eur J Cardiothorac Surg 2007; 31:698-702.
Tedford RJ, Hemnes AR, Russell SD. PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support. Circ Heart Fail 2008; 1:213-9.